Trademark Search in Canada

LIVIMMUNE

View On IC.GC.CA

CANCELLED

Last Applicant/ Owned by

CYTODYN INC.

Suite 660, 1111 Main StreetVancouver WA 98660

Serial Number

2061930 filed on 6^th Jul 2020

Registration Number

TMA1193309 registered on 9^th Aug 2023

Registration expiry Date

6^th Jul 2030

Correspondent Address

SMART & BIGGAR LP

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

M5H3Y2

LIVIMMUNE

Trademark usage description

therapeutic preparations, namely, therapeutic preparations for the treatment of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoho Read More

Classification Information

Class [005]
Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus- host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor.

Classification kind code

Class [042]
Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor.

Classification kind code

Class [044]
Providing health and medical information, and providing health and medical information in the field of therapeutic agents, preparations and substances for the prevention and treatment of HIV, cancer, graft-versus- host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders, COVID-19 via a website; providing medical information in the field of antibodies for use in targeting the CCR5 cell receptor via a website; medical analysis services, namely, medical analysis services for the diagnosis and treatment of persons with HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system diseases, respiratory diseases and disorders and COVID-19.

Classification kind code

Mark Details

Serial Number

2061930

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 1^st Mar 2022	Search Recorded
Submitted for opposition 20 on 1^st Mar 2022	Examiner's First Report
Submitted for opposition 223 on 1^st Mar 2022	Total Provisional Refusal
Submitted for opposition 256 on 6^th Sept 2021	Notification of Possible Opposition Sent
Submitted for opposition 48 on 22^nd Jun 2021	Agent Changed
Submitted for opposition 257 on 5^th Nov 2020	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 4^th Nov 2020	Created
Submitted for opposition 31 on 4^th Nov 2020	Formalized
Submitted for opposition 30 on 6^th Jul 2020	Filed
Submitted for opposition 228 on 6^th Jul 2020	International Registration